Phase 0-1 Clinical Trials

DTB和DCTD之间的合作推动了几种新的药效分析方法的开发，包括肿瘤组织活检组织中伽马双链断裂检测器的超灵敏免疫荧光分析，拓扑异构酶I和多聚ADP核糖聚合酶(PARP)的ELISA分析，以及其他DNA损伤标记物(PNBS1)的分析，MEK、ERK和AKT、DNmts的所有异构体，以及一系列免疫-PD标记物。这些分析是NIH临床中心已激活的新型非喜树碱拓扑异构酶I抑制剂、DNMT1抑制剂和免疫疗法组合的首次人体临床试验必不可少的。此外，与儿科肿瘤科的合作促进了用于罕见肿瘤的新药物的开发。围绕我们使用NCI 60进行系统药理学，已经开展了其他合作。

The collaboration between the DTB and DCTD has been responsible for the development of several new pharmacodynamic assays, including an ultrasensitive immunofluorescence assay for gamma H2AX (DNA double strand break detector) in tumor tissue biopsies, and ELISAs for topoisomerase I and poly ADP-ribose polymerase (PARP), as well as assays for other DNA damage markers (pNBS1), all of the isoforms of MEK, ERK, and AKT, DNMTs, as well as a series of immuno-PD markers. These assays have been essential for first in human clinical trials of novel non-camptothecin topoismerase I inhibitors, DNMT1 inibitors, and immunotherapy combinations that have been activated in the NIH Clinical Center. In addition, collaborations with the Pediatric Oncology Branch have facilitated the development of new agents used for rare tumors. Additional collaborations have developed around our use of the NCI 60 for systems pharmacology.